Results 1 to 10 of about 9,079 (152)
Pharmaceuticals, 2021 Dengue fever is an arbovirus disease caused by infection with the dengue virus (DENV). Half of the world’s population lives under the threat of dengue fever, however, researchers have yet to develop any drugs that are clinically applicable to this ...
Feng-Cheng Liu +2 more
exaly +3 more sources
Safety and Effectiveness of Micafungin in Neonates: A Retrospective Analytical Study from a Tertiary Pediatric Center [PDF]
Annals of Neonatology Journal, 2021 Background: The incidence of invasive fungal infections in neonatal intensive care units has increased dramatically over the past few decades, partly due to the increased survival rates of preterm neonates.
Kamile Arıkan +5 more
doaj +1 more source
In vitro interactions of nystatin and micafungin combined with chlorhexidine against Candida albicans isolates [PDF]
Current Medical Mycology, 2022 Background and Purpose: Oral candidiasis has become a growing problem in hospitals worldwide, and the development of antifungal drug resistance in Candida species constitutes a serious concern.
Maede Salehi +5 more
doaj +1 more source
Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication
Viruses, 2023 Echinocandin antifungal drugs, including micafungin, anidulafungin, and caspofungin, have been recently reported to exhibit antiviral effects against various viruses such as flavivirus, alphavirus, and coronavirus. In this study, we focused on micafungin
Shogo Nakajima +6 more
doaj +1 more source
A genome-wide screening of potential target genes to enhance the antifungal activity of micafungin in Schizosaccharomyces pombe. [PDF]
PLoS ONE, 2013 Micafungin is a non-reversible inhibitor of 1, 3-β-D-glucan synthase and interferes with fungal cell wall synthesis. Clinically, micafungin has been shown to be efficacious for the treatment of invasive candidiasis and invasive aspergillosis.
Xin Zhou +6 more
doaj +1 more source
Antibiotics, 2021 Micafungin is widely used for invasive candidiasis, especially in critically ill patients and those with cancer, and for empirical antifungal therapy in patients with neutropenic fever.
Saeed Alqahtani +5 more
doaj +1 more source
Antimicrobial Stewardship & Healthcare Epidemiology, 2023 Background: Fungal diseases are associated with substantial global mortality and economic burden, especially in critically ill or immunocompromised patients.
Radhika Arya +3 more
doaj +1 more source
Medical Mycology Case Reports, 2020 We report a rare case of C. krusei knee arthritis treated with instillation of micafungin and arthroscopy. A 49-year-old man hospitalized for treatment of Acute Myeloid Leukemia developed knee arthritis with C. krusei.
Jeroen C. van Egmond +3 more
doaj +1 more source
Tropical Medicine and Infectious Disease, 2022 Micafungin is the empiric antifungal agent of choice for the treatment of invasive candidiasis (IC). Pathophysiologic changes that occur in obese and/or critically ill patients can alter micafungin serum concentrations and the probability of target ...
Victoria C. Grant +5 more
doaj +1 more source
Journal of Infection in Developing Countries, 2021 Introduction: An echinocandin, such as micafungin, is recommended as first-line treatment for invasive Candida infections in immunocompromised patients. This multicenter, observational, prospective, non- interventional study evaluated the real-world use
Samo Zver +8 more
doaj +1 more source